Autopsy report · NCT00554775

WBRT & Erlotinib in Advanced NSCLC and Brain Metastases

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“IDMC made a recommendation to stop the trial as the target for continuing to the 2nd phase was not met.”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months before it started.
Ran for about 2 years 10 months before it stopped.
80 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: University College, London
Sponsor type: University, hospital or other
Conditions: Lung Cancer; Metastatic Cancer
Interventions: erlotinib hydrochloride; placebo
Participants: 80
Sites: 7
Countries: United Kingdom

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.